In August 2019, WBC 122,570 and BCR/ABL 49.92%. October 2019 the patient underwent
laparoscopic cholecystectomy. Developed benzodiazepine withdrawal in February 2020. CML
remained controlled on titrated doses of hydroxyurea.
October 2020, WBC 36,900. Blast 13%. November 2020 developed a psychotic episode
requiring psychiatric hospitalization. WBC 47,100, 16% blasts representing transition to
Accelerated Phase CML and started on Ponatinib.
November 2020, developed Ponatinib induced pancreatitis. Ponatinib discontinued in
December of 2020, but achieved a hematologic response.
Discussion:
Acute pancreatitis following TKI therapy is observed in case reports. Reported pancreatitis
induced by TKIs ranged from 0-4.3%. Ponatinib has been reported to lead to pancreatitis in up
to 6.7% of patients and may be dose dependent. Our case offers a unique prospective as we
describe a patient who develops acute pancreatitis on multiple different treatments including
Nilotinib, Ponatinib, and Omacetaxine. This results in a particularly challenging case to treat.
Pancreatitis in CML could be considered a serious impediment to therapy. Alternative agents
for consideration such as the ABL1 inhibitor Asciminib may be viable option.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES